Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 51

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 51
---
us supplement is a part of that registration statement. As permitted by SEC rules, this prospectus supplement does not contain
all of the information included in the registration statement and the accompanying exhibits and schedules we file with the SEC. You may
refer to the registration statement and the exhibits and schedules for more information about us and our securities.

Information and statements
contained in this prospectus supplement or any annex to this prospectus supplement are qualified in all respects by reference to the copy
of the relevant contract or other annex filed as an exhibit to the registration statement of which this prospectus supplement forms a
part.

Statements made in this prospectus
supplement concerning the contents of any contract, agreement or other document are not complete descriptions of all terms of these documents.
If a document has been filed as an exhibit to the registration statement, we refer you to the copy of the document that has been filed
for a complete description of its terms. Each statement in this prospectus supplement relating to a document filed as an exhibit is qualified
in all respects by the filed exhibit. You should read this prospectus supplement and the documents that we have filed as exhibits to the
registration statement of which this prospectus supplement is a part in their entirety.

We are subject to the informational
requirements of the Exchange Act. Accordingly, we will be required to file reports and other information with the SEC, including annual
reports on Form 20-F and reports on Form 6-K. The SEC maintains an internet website that contains reports and other information about
issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.

<div align='center'>S-32</div>

We are a “foreign private
issuer” as defined in Rule 3b-4 under the Securities Exchange Act of 1934, or the Exchange Act. As a result, our proxy solicitations
are not subject to the disclosure and procedural requirements of Regulation 14A under the Exchange Act and transactions in our equity
securities by our officers and directors are exempt from Section 16 of the Exchange Act. In addition, we are not required under the
Exchange Act to file periodic reports and financial statements as frequently or as promptly as U.S. companies whose securities are
registered under the Exchange Act. We publish annually an annual report filed on Form 20-F containing financial statements that have been
examined and reported on, with an opinion expressed by, a registered public accounting firm. We prepare our annual financial statements
in United